Page 1,837«..1020..1,8361,8371,8381,839..1,8501,860..»

Faulty gene may cut short male fertility

Posted: March 8, 2015 at 10:55 pm

New York, March 3 (IANS): A gene mutation could curtail sperm production and lead to early loss of fertility in men, says a study.

The study determined that loss of the gene that makes the protein TAF4b in male mice results in the premature exhaustion of their fertility.

The researchers noted that the process of sperm generation in mice may have direct applications to a similar loss of fertility in men.

"What is fascinating about these mice is they can reproduce," said senior study author Richard Freiman from Brown University in the US.

"Mice can usually reproduce until they are two years old, but these mice can only reproduce until they are four months old," said Freiman.

What the team discovered is that the loss of the gene that makes the protein TAF4b causes a deficit in the number of progenitor cells at an embryonic stage of a male mouse's reproductive development.

Lacking those important precursor cells means that the mice struggle to develop a robust stem cell infrastructure to sustain sperm production for the long term.

The affected mice are fertile at first, but quickly deplete the limited sperm supply that they can generate, the researchers pointed out.

TAF4b is a protein that affects how genes are regulated and transcribed, and its absence has profound impact on the reproductive system.

In previous work, Freiman's research group has shown that female mice without TAF4b are totally infertile and that their ovaries age prematurely.

See more here:
Faulty gene may cut short male fertility

Posted in New York Stem Cells | Comments Off on Faulty gene may cut short male fertility

Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange

Posted: March 8, 2015 at 10:55 pm

MENLO PARK, Calif., March 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer, will ring The Opening Bell of the New York Stock Exchange (NYSE) tomorrow, Thursday, March 5, 2015. Asterias began trading as an NYSE MKT listed company on October 8, 2014.

"New York Stock Exchange is a trusted partner to Asterias Biotherapeutics, and we are honored that the NYSE has invited our company to ring The Opening Bell," stated Mr. Lichtinger. "We believe our common stock listing on the NYSE MKT, the premier U.S. equities market for listing and trading of small growth companies, helps increase trading liquidity and provides greater exposure to a larger group of investors while increasing awareness of our promising therapeutic products that have the potential to address significant unmet medical needs using our stem cell technology platform. Of our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury has been cleared for a Phase 1/2a clinical trial and AST-VAC2 is expected to enter a Phase 1/2a clinical trial in lung cancer, and we are focused on executing our strategic plan in order to further advance these two products through meaningful clinical milestones."

Mr. Lichtinger will be joined by members of the Company's Board of Directors and management team. The NYSE Opening Bell will ring at 9:30 a.m. Eastern time and can be viewed live on the NYSE's website at https://nyse.nyx.com/the-bell/todays-bells-live. Photos and video of the NYSE bell ringing ceremony will also be available, courtesy of the NYSE, on Facebook (NYSE Euronext); Twitter (@NYSEEuronext) and on the NYSE YouTube Channel (nysetv1).

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' twotherapeutic programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. AST-OPC1 is currently in a Phase 1/2a clinical trial. Additional information about Asterias can be found at http://www.asteriasbiotherapeutics.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements

SOURCE Asterias Biotherapeutics, Inc.

RELATED LINKS http://www.asteriasbiotherapeutics.com

Continue reading here:
Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange

Posted in New York Stem Cells | Comments Off on Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange

Stem Cell Treatment India,Stem Cell Treatment India,Cost …

Posted: March 8, 2015 at 10:52 pm

Overview Stem cell treatment in India Stem cells are cells that retain the ability to renew themselves through mitotic cell division and can differentiate into a diverse range of specialized cell types. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin or intestinal tissues. Stem Cell Therapy in India Stem cells are the master cells of the human body. They can divide to produce copies of themselves and many other types of cell. They are found in various parts of the human body at every stage of development from embryo to adult.

Because stem cells are so versatile, they could potentially be used to repair and replace damaged human tissue.

The stem cells used in our experimental therapy are Mesenchymal stem cells, which are derived from your own bone marrow. These are multipotent stem cells that can transform into a variety of cell types, and thereby help in regeneration and repair of the diseased tissues.

For more information, medical assessment and medical quote send your detailed medical history and medical reports as email attachment to Email : - info@wecareindia.com Call: +91 9029304141 (10 am. To 8 pm. IST) (Only for international patients seeking treatment in India)

Stem Cell Treatment India offers info on India Stem Cell Treatment India, Low Cost Stem Cell Treatment India, Avascular Necrosis Stem Cell Treatment India, India Critical Limb Ischemia Treatment India, India End Stage Liver Disease Stem Cell Treatment India, Motor Neuron Disease Stem Cell Treatment India, Parkinsons Disease Treatment India, Psoriasis Stem Cell Treatment India, Spinal Cord Injury Stem Cell Treatment India, Vitiligo Stem Cell Treatment India, Stem Cell Cord Blood Banking India, Stem Cells India, Therapy India, Treatment India, Autism India, Cerebral Palsy India, Stem Cell Treatment On Brain Damage

Read this article:
Stem Cell Treatment India,Stem Cell Treatment India,Cost ...

Posted in Georgia Stem Cells | Comments Off on Stem Cell Treatment India,Stem Cell Treatment India,Cost …

Gordie Howes Son Says Dads Recovery No Fluke, Excited For Future Of Stem Cell Treatment

Posted: March 8, 2015 at 10:51 pm

By Ashley Dunkak @AshleyDunkak

CBS DETROIT Murray Howe, the head of the radiology department at ProMedica Toledo Hospital, understands the skepticism of those who question the stem cell treatment his father Gordie, also known as Mr. Hockey, received in December in Tijuana, Mexico.

Gordies health had been slowly declining even before the stroke he suffered in late October, and he was essentially bedridden when Murray and his brother Marty took him to Mexico to participate in a clinical trial. They did not have high hopes he was so far gone, Murray recalled but after each step of the two-part process, Gordie improved rapidly, once again able to walk and talk, repossessed of his wit and humor. Murray and his siblings were floored. So were the therapists who had been working with Gordie after his stroke.

Some physicians have scoffed at the idea of stem cells helping an individual who has had a stroke, but Murray a doctor himself says his fathers recovery after treatment opened his eyes to stem cells as a potential game-changer.

Speaking as a medical professional, its so frustrating when you cant really do anything for a patient, said Howe, the head of the radiology department at Toledo Hospital. You give them kind of a death sentence and you say, Well thats all you get. Theres nothing we can really offer. Its so sad. So now to be able to have on the brink of some huge hope for these patients is really, really exciting. As a medical professional, to me, theres never been anything more exciting in my entire career than this.

Murray does not blame people for being skeptical, and he agrees more research on the capabilities of stem cells is needed to show definitively what they can do. To say Murray is optimistic, however, would be a serious understatement.

Theres quite a few individuals out there who are calling themselves stem cell experts or this or that, kind of saying that theres no data to support that stem cells work on ischemic strokes, but thats really not true at all, Murray said. Theres at least 50 clinical studies that are going on across the world that are demonstrating its safety and working on demonstrating its efficacy, and the preliminary results on the ones that Ive seen are tremendous, so the data is clearly there. I think that people across the world in the next couple years are going to be as blown away as I was with our father when they see the power of stem cells and what they do for patients with not just stroke but with dementia and traumatic brain injuries and spinal cord injuries.

My dads case is by no means the only one, Murray continued. Hes kind of like in the middle. Theres examples of patients that have had a far greater result. Im so thrilled for my dad, but by no means was my dad a fluke or a random event. The studies are ongoing, and I think the point of any of the, I guess, naysayers is that Gordie Howe may be anecdotal and we need more research, and I totally agree with that. In fact, based on what weve seen with my father, I would say that we as a country and as a world should make a concerted effort to put as much time and energy as we can into investigating the power of stem cells because I really think that based on what Im seeing this is going to be a game-changer for medicine and a game-changer for quality of life for so many people that have non-option diseases like stroke or dementia.

Heading to Tijuana for treatment was a last-ditch effort to save Gordie, but it was not one the family undertook on a whim, Murray said.

Im well aware of hucksters and con games and this type of thing, and our family has never been about traveling the world to find the miracle cure, Murray said. Im a very mainstream physician. Ive always relied heavily on data and on long-term studies to prove the safety and efficacy of any treatment. For our father, we just our goal has always just been quality of life and comfort. When my mom was sick with her dementia that was our only priority was just keep her comfortable, keep her healthy, as healthy as possible, and keep her safe, and that was it. We had a number of people contact us saying, You know, we could help your mom with this pill and that pill, and I looked at everything that anybody presented to us, but to me there was nothing that showed any data that would made me want to experiment, if you will, with my mom.

Continue reading here:
Gordie Howes Son Says Dads Recovery No Fluke, Excited For Future Of Stem Cell Treatment

Posted in California Stem Cells | Comments Off on Gordie Howes Son Says Dads Recovery No Fluke, Excited For Future Of Stem Cell Treatment

'Big brain' gene found in humans, not chimps

Posted: March 8, 2015 at 10:50 pm

By Tia Ghose

New research suggests that a single gene may be responsible for the large number of neurons found uniquely in the human brain. When this gene was inserted in the brain of a mouse embryo (shown here), it induced the formation of many more neuron(Marta Florio and Wieland B. Huttner, Max Planck Institute of Molecular Cell Biology and Genetics)

A single gene may have paved the way for the rise of human intelligence by dramatically increasing the number of brain cells found in a key brain region.

This gene seems to be uniquely human: It is found in modern-day humans, Neanderthals and another branch of extinct humans called Denisovans, but not in chimpanzees.

By allowing the brain region called the neocortex to contain many more neurons, the tiny snippet of DNA may have laid the foundation for the human brain's massive expansion.

"It is so cool that one tiny gene alone may suffice to affect the phenotype of the stem cells, which contributed the most to the expansion of the neocortex," said study lead author Marta Florio, a doctoral candidate in molecular and cellular biology and genetics at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Still, it's likely this gene is just one of many genetic changes that make human cognition special, Florio said. [The Top 10 Things That Make Humans Special]

An expanding brain

The evolution from primitive apes to humans with complex language and culture has taken millions of years. Some 3.8 million ago, Australopithecus afarensis, the species typified by the iconic early human ancestor fossil Lucy, had a brain that was less than 30 cubic inches (500 cubic centimeters) in volume, or about a third the size of the modern human brain. By about 1.8 million years ago, Homo erectus was equipped with a brain that was roughly twice as big as that of Australopithecus. H. erectus also showed evidence of tool and fire use and more complex social groups.

Once anatomically modern humans, and their lost cousins the Neanderthals and Denisovans, arrived on the scene, the brain had expanded to roughly 85 cubic inches (1.4 liters) in volume. Most of this growth occurred in a brain region called the neocortex.

"The neocortex is so interesting because that's the seat of cognitive abilities, which, in a way, make us human like language and logical thinking," Florio told Live Science.

Originally posted here:
'Big brain' gene found in humans, not chimps

Posted in Washington Stem Cells | Comments Off on 'Big brain' gene found in humans, not chimps

Achieving gender equality in science, engineering and medicine

Posted: March 8, 2015 at 10:46 pm

(March 5, 2015) - Gender equality has not yet been achieved in science, medicine, and engineering, but The New York Stem Cell Foundation (NYSCF), through its Initiative on Women in Science and Engineering, is committed to making sure progress is made. NYSCF convened the Inaugural Meeting of its Initiative on Women in Science and Engineering (IWISE) Working Group in February 2014, where the group put forward seven actionable strategies for advancing women in science, medicine, and engineering, and reconvened in February 2015 to further develop the strategies.

NYSCF began this initiative after an analysis of its own programs. "We found that the ratio of men and women in our own programs was OK but it could certainly be improved," said Susan L. Solomon, CEO and Co-Founder, of NYSCF. "We wanted to take action and actually make tangible progress, so we brought together many of the leading men and women who have already committed time, energy, and resources towards this problem."

Today, the recommendations were published in Cell Stem Cell. They were divided into three categories: direct financial support strategies, psychological and cultural strategies, and major collaborative and international initiatives. The group chose to highlight the most high-impact and implementable strategies from a larger list developed during the meeting. They also sought to promote promising, long-term initiatives that will require significant collaboration among multiple stakeholders with the aim of connecting potential partners.

"Advancing women in science and medicine is of critical importance to the academic and research enterprise in our country," said Dr. Marc Tessier-Lavigne, President of Rockefeller University. "This paper is important as it not only brings attention to this key issue but also outlines creative strategies that can help break down barriers to gender equality in science."

Changing financing structures, embedded cultural norms, and tying funding to gender balance to enact real change are the pillars underlying the seven strategies recommended by the Working Group.

"The brain power provided by women in science is essential to sustaining a thriving US society and economy. It is time to move beyond just lamenting its loss and embrace the actions called for in this timely report," Dr. Claire Pomeroy, President, the Lasker Foundation and a member of the IWISE Working Group.

The seven strategies include:

1) Implement flexible family care spending 2) Provide "extra hands" awards 3) Recruit gender-balanced external review committees and speaker selection committees 4) Incorporate implicit bias statements 5) Focus on education as a tool 6) Create an institutional report card for gender equality 7) Partner to expand upon existing searchable databases of women in science, medicine, and engineering

The IWISE Working Group reconvened in February 2015 to continue to work on the Institutional Report Card for Gender Equality. The paper published today includes the proposed Phase 1 Institutional Report Card, and the group plans to release the Phase 2 report card once finalized.

###

View original post here:
Achieving gender equality in science, engineering and medicine

Posted in Cell Medicine | Comments Off on Achieving gender equality in science, engineering and medicine

Mesoblast refuses to rule out share raising

Posted: March 8, 2015 at 10:44 pm

Cash reserves at the end of December fell to $149.2 million, from $196.4 million at the end of June. Photo: Erin Jonasson

Regenerative medicine group Mesoblast has refused to rule out raising fresh funds from the sharemarket as it continues to burn about $25 million a quarter in its stem cell research programs, which has left it with an "18-month runway" with its existing cash reserves.

However, the preferred option is to pursue partnerships with other drug companies.

"There are a number of strategic partnerships" covering its tier one and tier two candidate treatments, chief financial officer Paul Hodgkinson said.

"Our disc program is our most advanced unpartnered program," chief executive Silviu Itescu said. "A partner with an established sales force would be the appropriate partner for us ... and they would take on the full cost of our development program."

Advertisement

It was the same with the company's rheumatoid arthritis research program, Mr Itescu said.

"Discussions are active and ongoing ... and clinical developments will be taken by our partner and the expected upfront [payment] would add substantially to our runway."

He also pointed to the prospects for attracting funds from Japan, Europe and the United States for the company's research.

Cash reserves at the end of December fell to $149.2 million, from $196.4 million at the end of June.

Read more:
Mesoblast refuses to rule out share raising

Posted in Regenerative Medicine | Comments Off on Mesoblast refuses to rule out share raising

Platelet Rich Plasma – PRP and Adult Stem Cell Therapy – Video

Posted: March 8, 2015 at 10:42 pm


Platelet Rich Plasma - PRP and Adult Stem Cell Therapy
DPM Debra Weinstock discusses #prp and #stemcell injections that may help you avoid surgery and alleviate your foot and ankle pain! #CrossBayFCC is located i...

By: Cross Bay Foot Care Center

Read more:
Platelet Rich Plasma - PRP and Adult Stem Cell Therapy - Video

Posted in Stem Cell Therapy | Comments Off on Platelet Rich Plasma – PRP and Adult Stem Cell Therapy – Video

'Miraculous' stem-cell treatment reverses symptoms of multiple sclerosis

Posted: March 8, 2015 at 10:42 pm

A new stem-cell treatment that reboots the entire immune system is enabling multiple sclerosis sufferers to walk, run and even dance again, in results branded "miraculous" by doctors.

Patients who have been wheelchair-bound for 10 years have regained the use of their legs in the ground-breaking therapy, while others who were blind can now see again. The treatment is the first to reverse the symptoms of MS, which is incurable, and affects about 100,000 people in Britain.

The two dozen patients who are taking part in the trials at the Royal Hallamshire Hospital, Sheffield, and Kings College Hospital, London, have effectively had their immune systems "rebooted". Although it is unclear what causes MS, some doctors believe it is the immune system itself that attacks the brain and spinal cord, leading to inflammation pain, disability and, in severe cases, death.

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patient's own blood.

Advertisement

"Since we started treating patients three years ago, some of the results we have seen have been miraculous," Prof Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, said.

"This is not a word I would use lightly, but we have seen profound neurological improvements."

Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter, Isla, two years ago. She claims the new treatment has transformed her life.

"It worked wonders," she said. "I remember being in the hospital ... after three weeks, I called my mum and said: 'I can stand'. We were all crying. I can run a little bit, I can dance. I love dancing, it is silly but I do."

However, specialists warn that patients need to be fit to benefit from the new treatment.

Visit link:
'Miraculous' stem-cell treatment reverses symptoms of multiple sclerosis

Posted in Stem Cell Therapy | Comments Off on 'Miraculous' stem-cell treatment reverses symptoms of multiple sclerosis

Quality control for adult stem cell treatment

Posted: March 8, 2015 at 10:42 pm

HEIDELBERG, 27 February 2015 - A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria. The strategy, which is published online in EMBO Molecular Medicine, is inspired by the approaches the biotechnology industry and regulatory affairs authorities have adopted for medicinal proteins produced from genetically engineered mammalian cells.

"Until now there has not been a systematic way to ensure that adult epidermal stem cells meet all the necessary requirements for safety before use as treatments for disease," says EMBO Member Yann Barrandon, Professor at Lausanne University Hospital, the Swiss Federal Institute of Technology in Lausanne and the lead author of the study. "We have devised a single cell strategy that is sufficiently scalable to assess the viability and safety of adult epidermal stem cells using an array of cell and molecular assays before the cells are used directly for the treatment of patients. We have used this strategy in a proof-of-concept study that involves treatment of a patient suffering from recessive dystrophic epidermolysis bullosa, a hereditary condition defined by the absence of type VII collagen which leads to severe blistering of the skin."

The researchers cultivated epidermal cells from the patient that can be used to regenerate skin. The scientists used their array of tests to determine which of the transduced cells met the necessary requirements for stemness - the characteristics of a stem cell that distinguish it from a regular cells - and safety. Clonal analysis revealed that the transduced stem cells varied in their ability to produce functional type VII collagen. When the most viable, modified stem cells were selected, transplantation onto immunodeficient mice regenerated skin that did not blister in the mouse model system for recessive dystrophic epidermolysis bullosa and produced functional type VII collagen. Safety was assessed by deter-mining the sites of integration of the viral vector, looking for rearrangements and hit genes, as well as whole genome sequencing.

"Our work shows that at least for adult epidermal stem cells it is possible to use a clonal strategy to deliver a level of safety that cannot be obtained by other gene therapy approaches. A clonal strategy should make it possible to integrate some of the more recent technologies for targeted genome editing that offer more precise ways to change genes in ways that may further benefit the treatment of disease. Further work is in progress in this direction."

###

A single epidermal stem cell strategy for safe ex vivo gene therapy

Stphanie Droz-Georget Lathion, Ariane Rochat, Graham Knott, Alessandra Recchia, Danielle Martinet, Sara Benmohammed, Nicolas Grasset, Andrea Zaffalon, Nathalie Besuchet Schmutz, Emmanuelle Savioz-Dayer, Jacques S. Beckmann, Jacques Rougemont, Fulvio Mavilio and Yann Barrandon

Read the paper:

http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201404353

Further information on EMBO Molecular Medicine is available at http://embomolmed.embopress.org/

More here:
Quality control for adult stem cell treatment

Posted in Stem Cell Therapy | Comments Off on Quality control for adult stem cell treatment

Page 1,837«..1020..1,8361,8371,8381,839..1,8501,860..»